keyword
MENU ▼
Read by QxMD icon Read
search

HFREF

keyword
https://www.readbyqxmd.com/read/28938247/challenges-with-percent-predicted-maximum-vo2-in-patients-with-heart-failure
#1
Clinton A Brawner, Jonathan K Ehrman, Ali Shafiq, Matthew A Saval, Stuart D Russell, David E Lanfear, Steven J Keteyian
PURPOSE: To describe the influence of different equations to predict maximum oxygen uptake (MVO2) on the percent predicted MVO2 (ppMVO2) and the resultant categorization of patients with heart failure with reduced ejection fraction (HFrEF) into high or low risk. METHODS: In this retrospective cohort study, ppMVO2 was calculated using six different equations to predict MVO2 among 1,168 patients with HFrEF (33% women). Repeated measures analysis of variance was used to compare within-subject differences in mean ppMVO2 between the prediction equations...
September 21, 2017: Medicine and Science in Sports and Exercise
https://www.readbyqxmd.com/read/28918108/heart-failure-with-recovered-ejection-fraction-in-african-americans-results-from-the-african-american-heart-failure-trial
#2
Kay-Won Chang, Neil Beri, Nghia H Nguyen, Boris Arbit, Sutton Fox, Sean Mojaver, Paul Clopton, S William Tam, Anne L Taylor, Jay N Cohn, Alan S Maisel, Inder S Anand
BACKGROUND: Recent studies have described the entity of heart failure with recovered ejection fraction (HFrecEF), but population specific studies remain lacking. The aim of this study was to characterize patients enrolled in the African-American Heart Failure Trial (A-HeFT) who had significant improvement in their ejection fraction (EF) during the first 6 months of follow-up. METHODS AND RESULTS: Subjects (n = 59) with HFrecEF (improvement in EF from < 35% to > 40% in 6 months) were compared to 259 with heart failure and persistently reduced EF (HFrEF), defined as EF ≤ 40% at 6 month follow-up...
September 13, 2017: Journal of Cardiac Failure
https://www.readbyqxmd.com/read/28917679/epidemiology-of-left-ventricular-systolic%C3%A2-dysfunction-and-heart-failure-in%C3%A2-the-framingham-study-an-echocardiographic-study-over-3-decades
#3
Ramachandran S Vasan, Vanessa Xanthakis, Asya Lyass, Charlotte Andersson, Connie Tsao, Susan Cheng, Jayashri Aragam, Emelia J Benjamin, Martin G Larson
OBJECTIVES: The purpose of this study was to describe the temporal trends in prevalence of left ventricular systolic dysfunction (LVSD) in individuals without and with heart failure (HF) in the community over a 3-decade period of observation. BACKGROUND: Temporal trends in the prevalence and management of major risk factors may affect the epidemiology of HF. METHODS: We compared the frequency, correlates, and prognosis of LVSD (left ventricular ejection fraction [LVEF] <50%) among Framingham Study participants without and with clinical HF in 3 decades (1985 to 1994, 1995 to 2004, and 2005 to 2014)...
September 9, 2017: JACC. Cardiovascular Imaging
https://www.readbyqxmd.com/read/28916479/dietary-nitrate-increases-vo2peak-and-performance-but-does-not-alter-ventilation-or-efficiency-in-patients-with-heart-failure-with-reduced-ejection-fraction
#4
Andrew R Coggan, Seth R Broadstreet, Kiran Mahmood, Deana Mikhalkova, Michael Madigan, Indra Bole, Soo Park, Joshua L Leibowitz, Ana Kadkhodayan, Deepak P Thomas, Dakkota Thies, Linda R Peterson
BACKGROUND: Patients with heart failure with reduced ejection fraction (HFrEF) exhibit lower efficiency, dyspnea, and diminished peak O2 uptake (VO2peak) during exercise. Dietary nitrate (NO3(-)), a source of nitric oxide (NO), has improved these measures in some studies of other populations. We determined the effects of acute NO3(-) ingestion on exercise responses in eight patients with HFrEF using a randomized, double-blind, placebo-controlled, crossover design. METHODS AND RESULTS: Plasma NO3(-), nitrite (NO2(-)), and breath NO were measured at multiple time points and respiratory gas exchange was determined during exercise after ingestion of beetroot juice containing or devoid of 11...
September 12, 2017: Journal of Cardiac Failure
https://www.readbyqxmd.com/read/28915854/medical-therapy-following-hospitalization-for-heart-failure-with-reduced-ejection-fraction-and-association-with-discharge-to-long-term-care-a-cross-sectional-analysis-of-the-reasons-for-geographic-and-racial-differences-in-stroke-regards-population
#5
Emily B Levitan, Melissa K Van Dyke, Ligong Chen, Raegan W Durant, Todd M Brown, J David Rhodes, Olusola Olubowale, Oluwole Muyiwa Adegbala, Meredith L Kilgore, Justin Blackburn, Karen C Albright, Monika M Safford
BACKGROUND: Less intensive treatment for heart failure with reduced ejection fraction (HFrEF) may be appropriate for patients in long-term care settings because of limited life expectancy, frailty, comorbidities, and emphasis on quality of life. METHODS: We compared treatment patterns between REasons for Geographic And Racial Differences in Stroke (REGARDS) study participants discharged to long-term care versus home following HFrEF hospitalizations. We examined medical records and Medicare pharmacy claims for 147 HFrEF hospitalizations among 80 participants to obtain information about discharge disposition and medication prescriptions and fills...
September 16, 2017: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/28912121/cortical-bone-stem-cell-therapy-preserves-cardiac-structure-and-function-after-myocardial-infarction
#6
Thomas E Sharp, Giana J Schena, Alexander R Hoachlandr-Hobby, Timothy Starosta, Remus M Berretta, Markus Wallner, Giulia Borghetti, Polina Gross, Daohai Yu, Jaslyn Johnson, Eric A Feldsott, Danielle M Trappanese, Amir Toib, Joseph E Rabinowitz, Jon C George, Hajime Kubo, Sadia Mohsin, Steven R Houser
Rationale: Cortical bone stem cells (CBSCs) have been shown to reduce ventricular remodeling and improve cardiac function in a murine myocardial infarction (MI) model. These effects were superior to other stem cell types that have been used in recent early stage clinical trials. However, CBSC efficacy has not been tested in a preclinical large animal model using approaches that could be applied to patients. Objective: To determine if post-MI transendocardial injection of allogeneic CBSCs reduces pathological structural and functional remodeling and prevents the development of heart failure in a swine MI model...
September 14, 2017: Circulation Research
https://www.readbyqxmd.com/read/28901848/pulmonary-hypertension-secondary-to-left-heart-disease
#7
Ghazal Kabbach, Debabrata Mukherjee
Pulmonary hypertension (PH) related to left heart disease (LHD) is the most common form of PH, accounting for more than two third of all PH cases. The hemodynamic abnormalities seen in PH-LHD are complex, and there are currently minimal evidence-based recommendations for the management of PH-LHD. While it is accepted that PH in the context of left heart disease is a marker of worse prognosis, it remains unclear whether its primary treatment is beneficial or harmful. In this article, we discuss the prevalence and significance of PH in patients with heart failure (HF) with reduced ejection fraction (HFrEF) as well as HF with preserved ejection fraction (HFpEF), and those with valvular heart disease and provide insights into the complex pathophysiology of cardiopulmonary interrelationship in individuals with PH due to left heart disease...
September 12, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28883863/the-evolution-of-natriuretic-peptide-augmentation-in-management-of-heart-failure-and-the-role-of-sacubitril-valsartan
#8
Srikanth Yandrapalli, Wilbert S Aronow, Pratik Mondal, David R Chabbott
Heart failure (HF) is one of the leading causes of morbidity, mortality, and health care expenditures in the US and worldwide. For three decades, the pillars of treatment of HF with reduced ejection fraction (HFrEF) were medications that targeted the sympathetic nervous system (SNS) and the renin-angiotensin-aldosterone system (RAAS). Prior attempts to augment the natriuretic peptide system (NPS) for the management of HF failed either due to lack of significant clinical benefit or due to the unacceptable side effect profile...
August 2017: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/28883225/anemia-is-associated-with-blunted-response-to-%C3%AE-blocker-therapy-using-carvedilol%C3%A3-insights-from-japanese-chronic-heart-failure-j-chf-study
#9
Yuji Nagatomo, Tsutomu Yoshikawa, Hiroshi Okamoto, Akira Kitabatake, Masatsugu Hori
BACKGROUND: Anemia portends a poor clinical outcome in patients with chronic heart failure (CHF). However, its mechanism remains unknown. We sought to elucidate the effect of anemia on patients with HF with reduced ejection fraction (HFrEF) who receive carvedilol therapy.Methods and Results:J-CHF study was a prospective, randomized, multicenter trial that assigned 360 HFrEF patients to 2.5 mg/5 mg/20 mg carvedilol groups according to the target dose. At baseline 70 patients (19%) had anemia ([A]) defined as hemoglobin level (Hb) <13 g/dL (male) or <12 g/dL (female) and the remaining 290 did not ([N])...
September 7, 2017: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/28882290/the-potential-of-clinical-phenotyping-of-heart%C3%A2-failure-with-imaging-biomarkers-for%C3%A2-guiding%C3%A2-therapies-a-focused-update
#10
REVIEW
Partho P Sengupta, Christopher M Kramer, Jagat Narula, Vasken Dilsizian
The need for noninvasive assessment of cardiac volumes and ejection fraction (EF) ushered in the use of cardiac imaging techniques in heart failure (HF) trials that investigated the roles of pharmacological and device-based therapies. However, in contrast to HF with reduced EF (HFrEF), modern HF pharmacotherapy has not improved outcomes in HF with preserved EF (HFpEF), largely attributed to patient heterogeneity and incomplete understanding of pathophysiological insights underlying the clinical presentations of HFpEF...
September 2017: JACC. Cardiovascular Imaging
https://www.readbyqxmd.com/read/28875746/plasma-renin-activity-in-patients-with-heart-failure-and-reduced-ejection-fraction-on-optimal-medical-therapy
#11
Petra Nijst, Frederik H Verbrugge, Pieter Martens, Philippe B Bertrand, Matthias Dupont, Gary S Francis, Wh Wilson Tang, Wilfried Mullens
BACKGROUND: Renin-angiotensin-aldosterone system (RAAS) activation in heart failure with reduced ejection fraction (HFREF) is detrimental through promotion of ventricular remodeling and salt and water retention. AIMS: The aims of this article are to describe RAAS activity in distinct HFREF populations and to assess its prognostic impact. METHODS: Venous blood samples were prospectively obtained in 76 healthy volunteers, 72 patients hospitalized for acute decompensated HFREF, and 78 ambulatory chronic HFREF patients without clinical signs of congestion...
July 2017: Journal of the Renin-angiotensin-aldosterone System: JRAAS
https://www.readbyqxmd.com/read/28873219/treatment-effectiveness-in-heart-failure-with-comorbidity-lung-disease-and-kidney-disease
#12
Jerry H Gurwitz, David J Magid, David H Smith, Grace H Tabada, Sue Hee Sung, Larry A Allen, David D McManus, Robert J Goldberg, Mayra Tisminetzky, Alan S Go
OBJECTIVES: To assess the clinical effectiveness of beta-blocker therapy in individuals with heart failure (HF) and chronic lung disease and of angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers (ARBs) in individuals with HF and chronic kidney disease. DESIGN: Retrospective cohort study. SETTING: Community. PARTICIPANTS: Individuals with HF with reduced ejection fraction (HFrEF) or HF with preserved ejection fraction (HFpEF)...
September 5, 2017: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/28872259/prevalence-and-prognostic-importance-of-precipitating-factors-leading-to-heart-failure-hospitalization-recurrent-hospitalizations-and-mortality
#13
Elke Platz, Pardeep S Jhund, Brian L Claggett, Marc A Pfeffer, Karl Swedberg, Christopher B Granger, Salim Yusuf, Scott D Solomon, John J McMurray
AIMS: Hospitalizations for heart failure (HF) are common and are associated with significant morbidity, mortality and cost. However, precipitating factors leading to HF hospitalization and their importance with respect to subsequent outcomes are not well understood. METHODS AND RESULTS: The symptoms and signs present at admission and investigator-identified factors thought to have contributed to the first adjudicated HF hospitalization in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programme were prospectively collected and stratified by ejection fraction (EF)...
September 4, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28870770/mechanisms-of-the-improvement-in-peak-vo2-with-exercise-training-in-heart-failure-with-reduced-or-preserved-ejection-fraction
#14
REVIEW
Wesley J Tucker, Cecilia C Lijauco, Christopher M Hearon, Siddhartha S Angadi, Michael D Nelson, Satyam Sarma, Shane Nanayakkara, André La Gerche, Mark J Haykowsky
Heart failure (HF) is a major health care burden associated with high morbidity and mortality. Approximately 50% of HF patients have reduced ejection fraction (HFrEF) while the remainder of patients have preserved ejection fraction (HFpEF). A hallmark of both HF phenotypes is dyspnoea upon exertion and severe exercise intolerance secondary to impaired oxygen delivery and/or use by exercising skeletal muscle. Exercise training is a safe and effective intervention to improve peak oxygen uptake (VO2peak) and quality of life in clinically stable HF patients, however, evidence to date suggests that the mechanism of this improvement appears to be related to underlying HF phenotype...
August 4, 2017: Heart, Lung & Circulation
https://www.readbyqxmd.com/read/28864134/rationale-and-design-of-a-prospective-study-to-assess-the-effect-of-left-cardiac-sympathetic-denervation-in-chronic-heart-failure
#15
Ashley Chin, Mpiko Ntsekhe, Charle Viljoen, Johan Rossouw, Tim Pennel, Peter J Schwartz
BACKGROUND: The main causes of mortality in patients with chronic heart failure include sudden cardiac death (SCD) and progressive heart failure. Autonomic dysfunction plays a detrimental role in the progression of chronic heart failure. Left cardiac sympathetic denervation (LCSD) is an inexpensive and safe procedure which modifies autonomic innervation of the heart and is associated with a significant antifibrillatory effect. Whether LCSD reduces the risk of SCD, delays progression of heart failure and improves quality of life in patients with heart failure with reduced ejection fraction (HFrEF) is not known...
August 8, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28859754/evolution-of-functional-mitral-regurgitation-and-prognosis-in-medically%C3%A2-managed-heart-failure-patients%C3%A2-with-reduced-ejection-fraction
#16
Riwa Nasser, Lauranne Van Assche, Anne Vorlat, Tom Vermeulen, Emeline Van Craenenbroeck, Viviane Conraads, Vicky Van der Meiren, Bharati Shivalkar, Paul Van Herck, Marc J Claeys
OBJECTIVES: The purpose of this study was to assess whether medical management may alter the severity of functional mitral regurgitation (FMR) and its prognosis in patients who have heart failure with reduced ejection fraction (HFrEF). BACKGROUND: FMR in patients who have HFrEF is associated with a worse prognosis. It is uncertain to what extent medical management may alter the severity of FMR and its prognosis. METHODS: The extent of FMR was assessed at baseline and after a median follow-up period of 50 months in 163 consecutive HFrEF patients (left ventricular ejection fraction <40%)...
September 2017: JACC. Heart Failure
https://www.readbyqxmd.com/read/28845316/acute-heart-failure-exacerbation-with-cardiogenic-shock-and-elevated-systemic-vascular-resistance-treated-with-a-combination-of-nicardipine-and-dobutamine-therapy
#17
Lydia E Issac, Setri Fugar, Naser Yamani, Burhan Mohamedali
Acute heart failure is a common reason for hospital admission and is usually caused by decreased cardiac output either as a result of an intrinsic cardiac issue or as a result of severe hypertension with elevated afterload. We present a patient with a history of HFrEF who presented with acute heart failure, found to have hypotension requiring Dobutamine support and an elevated systemic vascular resistance requiring Nicardipine drip, with subsequent recovery of cardiac function.
2017: Case Reports in Cardiology
https://www.readbyqxmd.com/read/28844335/sacubitril-valsartan-an-important-piece-in-the-therapeutic-puzzle-of-heart-failure
#18
REVIEW
Pedro Marques da Silva, Carlos Aguiar
Sacubitril/valsartan (LCZ696), a supramolecular sodium salt complex of the neprilysin inhibitor prodrug sacubitril and the angiotensin receptor blocker (ARB) valsartan, was recently approved in the EU and the USA for the treatment of chronic heart failure (HF) with reduced ejection fraction (HFrEF) (NYHA class II-IV). Inhibition of chronically activated neurohormonal pathways (the renin-angiotensin-aldosterone system [RAAS] and sympathetic nervous system [SNS]) is central to the treatment of chronic HFrEF. Furthermore, enhancement of the natriuretic peptide (NP) system, with favorable cardiovascular (CV) and renal effects in HF, is a desirable therapeutic goal to complement RAAS and SNS blockade...
August 23, 2017: Portuguese Journal of Cardiology: An Official Journal of the Portuguese Society of Cardiology
https://www.readbyqxmd.com/read/28840572/pharmacologic-management-for-heart-failure-and-emerging-therapies
#19
REVIEW
Diana H Kim, Feng-Ju Chien, Howard J Eisen
PURPOSE OF REVIEW: This review aims to summarize the growing body of literature of HF with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) with a focus on recent pharmacologics. RECENT FINDINGS: HFrEF continues to be more widely investigated than HFpEF. Ivabradine and combinatorial treatment with sacubitril and valsartan are promising newly approved therapies. Other experimental therapies have emerged, which include Serelaxin, Empagliflozin, Neuregulin, and Omecamtive mecarbil, among others...
August 24, 2017: Current Cardiology Reports
https://www.readbyqxmd.com/read/28835976/-medicinal-treatment-of-tricuspid-valve-regurgitation
#20
REVIEW
M Lankeit, K Keller, C Tschöpe, B Pieske
The vast majority of tricuspid valve regurgitations are of low degree without prognostic relevance in healthy individuals; however, morbidity and mortality increase with the degree of regurgitation, which can be secondary to either primary (structural) or secondary (functional) alterations of the valve. Due to the frequent lack of symptoms, echocardiographic examinations should be annually performed in patients with higher degree (at least moderate) tricuspid valve regurgitation, in particular in the presence of risk factors...
August 23, 2017: Herz
keyword
keyword
71067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"